Iktos
Anna Kriukova has a diverse range of work experience in the field of computational chemistry. From 2019 to the present, they have been a Senior Scientist at Iktos, where they are involved in the Structure-Based Drug Discovery team. Their work focuses on using AI to predict the binding affinity of small molecules to receptors. Anna collaborates with pharmaceutical and biotech companies to apply these methods in the search for new drugs to combat diseases such as cancer, malaria, and tuberculosis. Prior to this role, Anna was a Junior Scientist at Iktos from 2020 to 2023. Anna also had a Student Internship at Iktos from 2019 to 2020.
Additionally, Anna had a Student Internship at CEA - Commissariat à l'énergie atomique et aux énergies alternatives in 2019. Their work involved molecular modeling of peptide building blocks using sulfur and studying the force field of small peptides for conformational search. Their internship supervisor was Michel MONS, a Senior Researcher at CEA.
In 2018, Anna had a Student Internship at Institut des Sciences Chimiques de Rennes - UMR CNRS 6226.
Anna Kriukova pursued their education in chemistry, starting with a Bachelor's degree at the University of Rennes I from 2015 to 2018. Subsequently, they attended Sorbonne Université from 2018 to 2020 and obtained a Master's degree in chemistry.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.